Brief: TCR2 Therapeutics Announces Positive Topline Results From Phase 1 Portion Of Gavo-Cel Phase 1/2 Clinical Trial For Mesothelin-Expressing Solid Tumors
28/09/2022 11:54
Sept 28 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* GAVO-CEL CONTINUES TO DEMONSTRATE CLINICAL BENEFIT IN
SOLID
TUMORS WITH ADDITIONAL RECIST REPONSES IN OVARIAN CANCER AND
MESOTHELIOMA
* TCR2 THERAPEUTICS INC - PHASE 2 PORTION OF TRIAL UNDERWAY
IMPLEMENTING MULTIPLE APPROACHES TO FURTHER IMPROVE CLINICAL
OUTCOMES
* TCR2 THERAPEUTICS INC - SECOND RECIST PARTIAL RESPONSE IN
OVARIAN CANCER SUPPORTS BROAD POTENTIAL OF GAVO-CEL
* TCR2 THERAPEUTICS INC - POSITIVE TOPLINE RESULTS FROM
PHASE 1
PORTION OF GAVO-CEL PHASE 1/2 CLINICAL TRIAL FOR
MESOTHELIN-EXPRESSING SOLID TUMORS
Source text for Eikon: ID:nGNX4f2Byp
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview